{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:09:15Z","timestamp":1768003755181,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationships between headache frequency reductions and changes in AHM use in patients in PROMISE-2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PROMISE-2 was a double-blind, placebo-controlled trial conducted in adults with CM. Patients were randomized to eptinezumab 100\u2009mg, 300\u2009mg, or placebo, administered intravenously once every 12\u2009weeks for up to two doses. Patients recorded headache\/AHM information daily and for each event in an electronic diary; data from all days with daily reports were included. Shifts in headache frequency and AHM use were assessed in the three populations: total CM population, patients with CM and medication-overuse headache (MOH), and patients with CM and MOH who were\u2009\u2265\u200950% responders during treatment (response over weeks 1\u201324).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1072 adults with CM received treatment (eptinezumab, <jats:italic>n<\/jats:italic>\u2009=\u2009706; placebo, <jats:italic>n<\/jats:italic>\u2009=\u2009366). Mean baseline headache frequency was 20.5\u2009days; mean baseline AHM days was 13.4; 431 patients had MOH, of which 225 (52.2%) experienced \u226550% response over weeks 1\u201324. Relative to baseline, the proportion of days with both headache and AHM use decreased 25.1% (eptinezumab) versus 17.0% (placebo) in the total population (<jats:italic>N<\/jats:italic>\u2009=\u20091072), 29.2% versus 18.4% in the MOH subpopulation (<jats:italic>n<\/jats:italic>\u2009=\u2009431), and 38.3% versus 31.5% in the CM with MOH population with \u226550% response subgroup (<jats:italic>n<\/jats:italic>\u2009=\u2009225) during weeks 1\u201324. The proportion of days with headache and triptan use decreased 9.1% (eptinezumab) versus 5.8% (placebo), 11.8% versus 7.2%, and 14.5% versus 12.6%, respectively. Reductions in other AHM types were smaller.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this post hoc analysis, eptinezumab use in patients with CM was associated with greater decreases in days with headache with AHM overall and with triptans in particular. The magnitude of effect was greater in the subgroup of CM patients with MOH and\u2009\u2265\u200950% response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974153\">NCT02974153<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                <jats:p>Eptinezumab reduces headache frequency and acute medication use in patients with chronic migraine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01482-0","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:02:43Z","timestamp":1662444163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study"],"prefix":"10.1186","volume":"23","author":[{"given":"Robert P.","family":"Cowan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Marmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Schim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1482_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1212\/WNL.58.6.885","volume":"58","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Scher AI, Kolodner K et al (2002) Migraine in the United States: epidemiology and patterns of health care use. Neurology 58:885\u2013894. https:\/\/doi.org\/10.1212\/WNL.58.6.885","journal-title":"Neurology"},{"key":"1482_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/head.13588","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Munjal S, Buse DC et al (2019) Unmet acute treatment needs from the 2017 migraine in America symptoms and treatment study. Headache 59:1310\u20131323. https:\/\/doi.org\/10.1111\/head.13588","journal-title":"Headache"},{"key":"1482_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A et al (2018) Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache 58:1408\u20131426. https:\/\/doi.org\/10.1111\/head.13407","journal-title":"Headache"},{"key":"1482_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.mayocp.2019.11.025","volume":"95","author":"S Hutchinson","year":"2020","unstructured":"Hutchinson S, Lipton RB, Ailani J et al (2020) Characterization of acute prescription migraine medication use: results from the CaMEO study. Mayo Clin Proc 95:709\u2013718. https:\/\/doi.org\/10.1016\/j.mayocp.2019.11.025","journal-title":"Mayo Clin Proc"},{"key":"1482_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1517\/14740338.2015.1026325","volume":"14","author":"J Tajti","year":"2015","unstructured":"Tajti J, Majl\u00e1th Z, Szok D et al (2015) Drug safety in acute migraine treatment. Expert Opin Drug Saf 14:891\u2013909. https:\/\/doi.org\/10.1517\/14740338.2015.1026325","journal-title":"Expert Opin Drug Saf"},{"key":"1482_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0333102416660552","volume":"37","author":"K Thorlund","year":"2017","unstructured":"Thorlund K, Toor K, Wu P et al (2017) Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia 37:965\u2013978. https:\/\/doi.org\/10.1177\/0333102416660552","journal-title":"Cephalalgia"},{"key":"1482_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0875-x","volume":"19","author":"N Vandenbussche","year":"2018","unstructured":"Vandenbussche N, Laterza D, Lisicki M et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19:1\u201314. https:\/\/doi.org\/10.1186\/s10194-018-0875-x","journal-title":"J Headache Pain"},{"key":"1482_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"1482_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/s1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S et al (2019) Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 18:891\u2013902. https:\/\/doi.org\/10.1016\/s1474-4422(19)30146-2","journal-title":"Lancet Neurol"},{"key":"1482_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s10194-016-0696-8","volume":"17","author":"K Thorlund","year":"2016","unstructured":"Thorlund K, Sun-Edelstein C, Druyts E et al (2016) Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 17:107. https:\/\/doi.org\/10.1186\/s10194-016-0696-8","journal-title":"J Headache Pain"},{"key":"1482_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","volume":"19","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ, Alam A, Reed ML et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 19:38. https:\/\/doi.org\/10.1186\/s10194-018-0865-z","journal-title":"J Headache Pain"},{"key":"1482_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"1482_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.14218\/JCTH.2015.00052","volume":"4","author":"E Yoon","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M et al (2016) Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol 4:131\u2013142. https:\/\/doi.org\/10.14218\/JCTH.2015.00052","journal-title":"J Clin Transl Hepatol"},{"key":"1482_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4175","volume":"15","author":"C Sostres","year":"2013","unstructured":"Sostres C, Gargallo CJ, Lanas A (2013) Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 15:1\u20138. https:\/\/doi.org\/10.1186\/ar4175","journal-title":"Arthritis Res Ther"},{"key":"1482_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M et al (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"key":"1482_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2022.2049236","volume":"18","author":"S Benemei","year":"2022","unstructured":"Benemei S, Bentivegna E, Martelletti P (2022) Positioning the new drugs for migraine. Expert Opin Drug Metab Toxicol 18:1\u20133. https:\/\/doi.org\/10.1080\/17425255.2022.2049236","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1482_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/14712598.2021.1931678","volume":"21","author":"V Spuntarelli","year":"2021","unstructured":"Spuntarelli V, Negro A, Luciani M et al (2021) Eptinezumab for the treatment of migraine. Expert Opin Biol Ther 21:999\u20131011. https:\/\/doi.org\/10.1080\/14712598.2021.1931678","journal-title":"Expert Opin Biol Ther"},{"key":"1482_CR18","doi-asserted-by":"crossref","unstructured":"Ambat FDF, Bentivegna E, Martelletti P (2022) Novel migraine therapies may reduce public and personal disadvantages for people with migraine. BioDrugs\u00a036:337-330","DOI":"10.1007\/s40259-022-00532-y"},{"key":"1482_CR19","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94:e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"key":"1482_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658","journal-title":"Cephalalgia"},{"key":"1482_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"H-C Diener","year":"2021","unstructured":"Diener H-C, Marmura MJ, Tepper SJ et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 61:125\u2013136. https:\/\/doi.org\/10.1111\/head.14036","journal-title":"Headache"},{"key":"1482_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2022.01.006","volume":"44","author":"V Martin","year":"2022","unstructured":"Martin V, Nagy AJ, Janelidze M et al (2022) Impact of baseline characteristics on the efficacy and safety of Eptinezumab in patients with migraine: subgroup analyses of PROMISE-1 and PROMISE-2. Clin Ther 44:389\u2013402. https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.006","journal-title":"Clin Ther"},{"key":"1482_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/S10194-022-01418-8","volume":"23","author":"R Apelian","year":"2022","unstructured":"Apelian R, Boyle L, Hirman J, Asher D (2022) Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. J Headache Pain 23:48. https:\/\/doi.org\/10.1186\/S10194-022-01418-8","journal-title":"J Headache Pain"},{"key":"1482_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, di Tanna GL, Lipton RB et al (2019) Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. Pharmacoeconomics 3:411\u2013417. https:\/\/doi.org\/10.1007\/s41669-018-0105-0","journal-title":"Pharmacoeconomics"},{"key":"1482_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s004150050560","volume":"247","author":"AJ de Craen","year":"2000","unstructured":"de Craen AJ, Tijssen JGP, de Gans J, Kleijnen J (2000) Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 247:183\u2013188","journal-title":"J Neurol"},{"key":"1482_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10194-007-0360-4","volume":"8","author":"F Antonaci","year":"2007","unstructured":"Antonaci F, Chimento P, Diener HC et al (2007) Lessons from placebo effects in migraine treatment. J Headache Pain 8:63\u201366. https:\/\/doi.org\/10.1007\/s10194-007-0360-4","journal-title":"J Headache Pain"},{"key":"1482_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000110117","volume":"6","author":"JR Couch Jr","year":"1987","unstructured":"Couch JR Jr (1987) Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 6:178\u2013185. https:\/\/doi.org\/10.1159\/000110117","journal-title":"Neuroepidemiology"},{"key":"1482_CR28","doi-asserted-by":"publisher","first-page":"218ra5","DOI":"10.1126\/scitranslmed.3006175","volume":"6","author":"S Kam-Hansen","year":"2014","unstructured":"Kam-Hansen S, Jakubowski M, Kelley JM et al (2014) Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med 6:218ra5. https:\/\/doi.org\/10.1126\/scitranslmed.3006175","journal-title":"Sci Transl Med"},{"key":"1482_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/j.pain.0000000000002365","volume":"163","author":"DB Swerts","year":"2022","unstructured":"Swerts DB, Benedetti F, Peres MFP (2022) Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis. Pain 163:415\u2013424. https:\/\/doi.org\/10.1097\/j.pain.0000000000002365","journal-title":"Pain"},{"key":"1482_CR30","doi-asserted-by":"publisher","unstructured":"McAllister P, Kudrow D, Cady R et al (2022) Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia 3331024221089567. https:\/\/doi.org\/10.1177\/03331024221089567","DOI":"10.1177\/03331024221089567"},{"key":"1482_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9061704","volume":"9","author":"J Gameiro","year":"2020","unstructured":"Gameiro J, Fonseca JA, Outerelo C, Lopes JA (2020) Acute kidney injury: from diagnosis to prevention and treatment strategies. J Clin Med 9:1\u201321. https:\/\/doi.org\/10.3390\/jcm9061704","journal-title":"J Clin Med"},{"key":"1482_CR32","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/ph3041279","volume":"3","author":"M Dixit","year":"2010","unstructured":"Dixit M, Doan T, Kirschner R, Dixit N (2010) Significant acute kidney injury due to non-steroidal antiinflammatory drugs: inpatient setting. Pharmaceuticals 3:1279\u20131285. https:\/\/doi.org\/10.3390\/ph3041279","journal-title":"Pharmaceuticals"},{"key":"1482_CR33","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1212\/01.wnl.0000240128.76399.fa","volume":"67","author":"EA Wammes-van der Heijden","year":"2006","unstructured":"Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM et al (2006) Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 67:1128\u20131134. https:\/\/doi.org\/10.1212\/01.wnl.0000240128.76399.fa","journal-title":"Neurology"},{"key":"1482_CR34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N et al (2018) Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 58:700\u2013714. https:\/\/doi.org\/10.1111\/head.13275","journal-title":"Headache"},{"key":"1482_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1526-4610.2011.02050.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Pearlman SH, Reed ML et al (2012) Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 52:18\u201336. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02050.x","journal-title":"Headache"},{"key":"1482_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37:631\u2013649. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"key":"1482_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/thg.2016.46","volume":"19","author":"Y Yang","year":"2016","unstructured":"Yang Y, Zhao H, Heath AC et al (2016) Shared genetic factors underlie migraine and depression. Twin Res Hum Genet 19:341\u2013350. https:\/\/doi.org\/10.1017\/thg.2016.46","journal-title":"Twin Res Hum Genet"},{"key":"1482_CR38","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1212\/WNL.0b013e3181cbcd19","volume":"74","author":"A Stam","year":"2010","unstructured":"Stam A, de Vries B, Janssens A et al (2010) Shared genetic factors in migraine and depression: evidence from a genetic isolate. Neurology 74:288\u2013294. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cbcd19","journal-title":"Neurology"},{"key":"1482_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"H-C Diener","year":"2016","unstructured":"Diener H-C, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"key":"1482_CR40","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.14206","volume":"61","author":"MJ Marmura","year":"2021","unstructured":"Marmura MJ, Diener HC, Cowan RP et al (2021) Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Headache 61:1421\u20131431. https:\/\/doi.org\/10.1111\/head.14206","journal-title":"Headache"},{"key":"1482_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.18553\/jmcp.2017.23.11.1169","volume":"23","author":"M Bonafede","year":"2017","unstructured":"Bonafede M, Cai Q, Cappell K et al (2017) Factors associated with direct health care costs among patients with migraine. J Manag Care Spec Pharm 23:1169\u20131176. https:\/\/doi.org\/10.18553\/jmcp.2017.23.11.1169","journal-title":"J Manag Care Spec Pharm"},{"key":"1482_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2020.571035","volume":"14","author":"S Migliore","year":"2020","unstructured":"Migliore S, Paolucci M, Quintiliani L et al (2020) Psychopathological comorbidities and clinical variables in patients with medication overuse headache. Front Hum Neurosci 14:571035. https:\/\/doi.org\/10.3389\/fnhum.2020.571035","journal-title":"Front Hum Neurosci"},{"key":"1482_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/head.14056","volume":"61","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Hentz JG, Sahai-Srivastava S et al (2021) Headache characteristics and burden from chronic migraine with medication overuse headache: cross-sectional observations from the medication overuse treatment strategy trial. Headache 61:351\u2013362. https:\/\/doi.org\/10.1111\/head.14056","journal-title":"Headache"},{"key":"1482_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE et al (2021) Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract 11:216\u2013226. https:\/\/doi.org\/10.1212\/CPJ.0000000000001037","journal-title":"Neurol Clin Pract"},{"key":"1482_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20:1\u201311. https:\/\/doi.org\/10.1186\/S10194-019-0993-0","journal-title":"J Headache Pain"},{"key":"1482_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11916-021-00982-z","volume":"25","author":"SK Parikh","year":"2021","unstructured":"Parikh SK, Kempner J, Young WB (2021) Stigma and migraine: developing effective interventions. Curr Pain Headache Rep 25:75. https:\/\/doi.org\/10.1007\/s11916-021-00982-z","journal-title":"Curr Pain Headache Rep"},{"key":"1482_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11916-019-0743-7","volume":"23","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Young WB (2019) Migraine: stigma in society. Curr Pain Headache Rep 23:1\u20136. https:\/\/doi.org\/10.1007\/S11916-019-0743-7","journal-title":"Curr Pain Headache Rep"},{"key":"1482_CR48","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/head.14151","volume":"61","author":"PM Estave","year":"2021","unstructured":"Estave PM, Beeghly S, Anderson R et al (2021) Learning the full impact of migraine through patient voices: a qualitative study. Headache 61:1004\u20131020. https:\/\/doi.org\/10.1111\/head.14151","journal-title":"Headache"},{"key":"1482_CR49","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1468-2982.2008.01644.x","volume":"28","author":"F Radat","year":"2008","unstructured":"Radat F, Mekies C, G\u00e9raud G et al (2008) Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study. Cephalalgia 28:1115\u20131125. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01644.x","journal-title":"Cephalalgia"},{"key":"1482_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10194-007-0361-3","volume":"8","author":"MFP Peres","year":"2007","unstructured":"Peres MFP, Mercante JPP, Guendler VZ et al (2007) Cephalalgiaphobia: a possible specific phobiaof illness. J Headache Pain 8:56\u201359. https:\/\/doi.org\/10.1007\/s10194-007-0361-3","journal-title":"J Headache Pain"},{"key":"1482_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1129-2377-14-49","volume":"14","author":"G Giannini","year":"2013","unstructured":"Giannini G, Zanigni S, Grimaldi D et al (2013) Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study. J Headache Pain 14:49. https:\/\/doi.org\/10.1186\/1129-2377-14-49","journal-title":"J Headache Pain"},{"key":"1482_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pain.2005.09.010","volume":"118","author":"M Lanteri-Minet","year":"2005","unstructured":"Lanteri-Minet M, Radat F, Chautard MH, Lucas C (2005) Anxiety and depression associated with migraine: influence on migraine subjects\u2019 disability and quality of life, and acute migraine management. Pain 118:319\u2013326. https:\/\/doi.org\/10.1016\/j.pain.2005.09.010","journal-title":"Pain"},{"key":"1482_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-022-01429-5","volume":"23","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gallop K, Smith T et al (2022) Real-world experience of interictal burden and treatment in migraine: a qualitative interview study. J Headache Pain 23:65. https:\/\/doi.org\/10.1186\/s10194-022-01429-5","journal-title":"J Headache Pain"},{"key":"1482_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/head.13306","volume":"58","author":"ELH Spierings","year":"2018","unstructured":"Spierings ELH, Khan A, Cady R et al (2018) Baseline population characteristics of PROMISE-2: a phase 3, randomized, double-blind, placebo-controlled study of Eptinezumab for prevention of chronic migraine (PF34). Headache 58:98\u201399. https:\/\/doi.org\/10.1111\/head.13306","journal-title":"Headache"},{"key":"1482_CR55","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/wnl.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D et al (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688\u2013695. https:\/\/doi.org\/10.1212\/wnl.0000000000001256","journal-title":"Neurology"},{"key":"1482_CR56","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/head.14177","volume":"61","author":"LN Carlsen","year":"2021","unstructured":"Carlsen LN, Rouw C, Westergaard ML et al (2021) Treatment of medication overuse headache: effect and predictors after 1 year\u2014a randomized controlled trial. Headache 61:1112\u20131122. https:\/\/doi.org\/10.1111\/head.14177","journal-title":"Headache"},{"key":"1482_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1517\/14740338.1.4.331","volume":"1","author":"G Fritsche","year":"2002","unstructured":"Fritsche G, Diener HC (2002) Medication overuse headaches - what is new? Expert Opin Drug Saf 1:331\u2013338. https:\/\/doi.org\/10.1517\/14740338.1.4.331","journal-title":"Expert Opin Drug Saf"},{"key":"1482_CR58","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J et al (2019) Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet 394:1560\u20131579. https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9","journal-title":"Lancet"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01482-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01482-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01482-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:02:46Z","timestamp":1662444166000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01482-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01482-0","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"23 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was provided by the independent ethics committee or institutional review board of the study\u00a0site. The study was conducted in accordance with Good Clinical Practice guidelines, the principles of the\u00a0Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior\u00a0to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RPC has been a consultant and\/or advisory board member for Alder, Allergan, Amgen, ATI, electroCore, eNeura, Novartis, Teva, and Zosano; served on a speaker\u2019s bureau for Biohaven; as an expert consultant for GLG, Guidepoint Global, Impel, Satsuma, Spherix Global Insights, Teva, Theranica, XOC, and Zosano; and received royalties from Penguin\/Avery and Springer.MM has received grants for research (no personal compensation) from Allergan\/AbbVie, electroCore, and Teva; served as a consultant and\/or advisory board member for Alder\/Lundbeck, Amgen\/Novartis, and Theranica; participated in a speaker\u2019s bureau for Amgen\/ Novartis and Eli Lilly; and received royalties from Cambridge, Demos Medical, and MedLink.HD has received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations over the last 3\u2009years from Allergan, Eli Lilly, Lundbeck, MSD, Novartis, Pfizer, Teva, and Weber & Weber; headache research support from the German Research Council (DFG); and served on editorial boards for <i>Cephalalgia, Lancet Neurology,<\/i> and <i>Drugs<\/i>.AS has received consulting fees from Alder, Amgen, Eli Lilly, eNeura, Impel, Lundbeck, Novartis, and Theranica.JS has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Avanir, Depomed, electroCore, Eli Lilly, Novartis, Pernix, Promius, Supernus, Teva Pharmaceuticals, and Upsher-Smith; holds stock and\/or stock options in Alder\/Lundbeck, which sponsored research in which JS was involved as an investigator; and has received research support from Allergan, Amgen, and Eli Lilly.JH is an employee of Pacific Northwest Statistical Consulting, Inc., a contracted service provider of biostatistical resources for H. Lundbeck A\/S.TB and RC were employees of Lundbeck or one of its subsidiary companies at the time of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}